We are live on ! Find out more
VanEck Associates

VanEck Associates Portfolio holdings

AUM $133B
1-Year Est. Return 72.99%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$133B
AUM Growth
+$12.2B
Cap. Flow
+$7.34B
Cap. Flow %
5.51%
Top 10 Hldgs %
31.59%
Holding
1,470
New
67
Increased
946
Reduced
372
Closed
66

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$1.09B
2
AEM icon
Agnico Eagle Mines
AEM
+$830M
3
AVGO icon
Broadcom
AVGO
+$763M
4
NEM icon
Newmont
NEM
+$717M
5
TSM icon
TSMC
TSM
+$618M

Sector Composition

Rank Sector Weight
1 Technology 41.47%
2 Materials 28.65%
3 Industrials 6.66%
4 Energy 5.06%
5 Healthcare 4.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MLCO icon
1301
Melco Resorts & Entertainment
MLCO
$2.12B
$104K ﹤0.01%
18,241
-3,268
-15% -$19.8K
CNTN
1302
Canton Strategic Holdings
CNTN
$161M
$103K ﹤0.01%
+31,500
New +$124K
OTLY
1303
Oatly Group
OTLY
$337M
$102K ﹤0.01%
10,079
-551
-5% -$6.11K
WDC icon
1304
Western Digital
WDC
$192B
$99K ﹤0.01%
367
+117
+47% +$30.5K
RARE icon
1305
Ultragenyx Pharmaceutical
RARE
$2.72B
$91K ﹤0.01%
4,357
-810
-16% -$18.2K
IEF icon
1306
iShares 7-10 Year Treasury Bond ETF
IEF
$47.1B
$86K ﹤0.01%
906
+21
+2% +$2.02K
MKC icon
1307
McCormick & Company Non-Voting
MKC
$14B
$85K ﹤0.01%
1,689
-106
-6% -$6.75K
LITE icon
1308
Lumentum
LITE
$64.6B
$84K ﹤0.01%
+119
New +$65.4K
TXG icon
1309
10x Genomics
TXG
$5.97B
$83K ﹤0.01%
3,903
+235
+6% +$4.7K
EDN
1310
Edenor
EDN
$1.19B
$80K ﹤0.01%
2,668
+1,631
+157% +$46K
HRL icon
1311
Hormel Foods
HRL
$13.9B
$80K ﹤0.01%
3,428
-361,060
-99% -$8.63M
WGS icon
1312
GeneDx Holdings
WGS
$1.86B
$77K ﹤0.01%
1,198
-39
-3% -$3.56K
QQQ icon
1313
Invesco QQQ Trust
QQQ
$469B
$76K ﹤0.01%
132
+6
+5% +$3.65K
TWST icon
1314
Twist Bioscience
TWST
$5.87B
$73K ﹤0.01%
1,543
-533
-26% -$23.9K
MAR icon
1315
Marriott International
MAR
$97.5B
$71K ﹤0.01%
+216
New +$71K
ITUB icon
1316
Itaú Unibanco
ITUB
$93.5B
$70K ﹤0.01%
8,408
-9,194
-52% -$76.9K
BEAM icon
1317
Beam Therapeutics
BEAM
$2.74B
$69K ﹤0.01%
2,884
-1,035
-26% -$28.7K
IVZ icon
1318
Invesco
IVZ
$13.5B
$69K ﹤0.01%
2,824
+50
+2% +$1.31K
OMCL icon
1319
Omnicell
OMCL
$1.86B
$66K ﹤0.01%
1,980
-314
-14% -$13.1K
LKFT
1320
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.88B
$65K ﹤0.01%
2,153
+185
+9% +$6.13K
LAUR icon
1321
Laureate Education
LAUR
$5.05B
$61K ﹤0.01%
1,757
-1,821
-51% -$62.4K
NTLA icon
1322
Intellia Therapeutics
NTLA
$1.56B
$59K ﹤0.01%
4,622
-769
-14% -$9.8K
RERE
1323
ATRenew
RERE
$848M
$59K ﹤0.01%
12,625
-7,169
-36% -$40.4K
CFR icon
1324
Cullen/Frost Bankers
CFR
$10.2B
$58K ﹤0.01%
+422
New +$58.3K
DKL icon
1325
Delek Logistics
DKL
$3.04B
$58K ﹤0.01%
1,101
-4,446
-80% -$229K

Similar funds

VanEck Associates's Q1 2026 Portfolio in Review

As of Q1 2026, VanEck Associates held 1,470 positions worth $133B, up 10% from $121B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

VanEck Associates deployed $7.34B of net new capital in Q1 2026, opening 67 new positions and adding to 946 existing holdings. Its largest new stake was United States Antimony: 10,369,695 shares worth $90.5M.

By sector, the portfolio is most concentrated in Technology at 41% of assets, down from 42% a quarter earlier, followed by Materials and Industrials.

On the sell side, the largest reduction was Pan American Silver, an estimated $1.04B trimmed.

  • VanEck Associates's largest Q1 2026 buy was United States Antimony: 10,369,695 shares worth $90.5M.
  • VanEck Associates added most to NVIDIA in Q1 2026, an estimated $1.09B increase.
  • VanEck Associates's biggest Q1 2026 reduction was Pan American Silver, cutting an estimated $1.04B.
  • VanEck Associates fully exited Ur-Energy in Q1 2026, selling an estimated $28.4M.
  • VanEck Associates's ten largest holdings make up 32% of its $133B portfolio in Q1 2026.
  • VanEck Associates opened 67 new positions and closed 66 in Q1 2026.
  • VanEck Associates's portfolio value rose 10% quarter-over-quarter to $133B.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.